RxDoctor Payments Data

Rafael Hasbun, MD

Internal Medicine · Marlton, NJNPI 1477533545

Payments from drug & device makers

$335in general payments, 2019–2025

Across 21 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$200
  • AbbVie$33
  • Abbott$25
  • Eisai Inc.$18
  • Lilly USA, LLC$18
  • Pfizer$17
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$200
AbbVie2$33
Abbott1$25
Eisai Inc.1$18
Lilly USA, LLC1$18
Pfizer1$17
GSK1$14
Sanofi Pasteur Inc.1$11

How this compares

$335 in reported general payments places this provider in the 45th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$62,624
Medicare patients
173
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$94,900
MounjaroTirzepatide38$50,735
EliquisApixaban48$49,529
JanuviaSitagliptin Phosphate37$40,799
JanumetSitagliptin Phos/Metformin Hcl19$25,888
JardianceEmpagliflozin19$23,832
LinzessLinaclotide21$15,894
XareltoRivaroxaban18$14,107
FarxigaDapagliflozin Propanediol15$10,874
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$6,465
Rosuvastatin Calcium302$5,449
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$5,014
Celecoxib79$4,631
Telmisartan-AmlodipineTelmisartan/Amlodipine13$4,244
Omeprazole242$3,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$200$94,90081 claims
Lilly USA, LLCMounjaro$18$50,73538 claims
PfizerEliquis$17$49,52948 claims
AbbVieLinzess$33$15,89421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →